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Summary
OBJECTIVE To compare effectiveness and tolera-
bility of quinagolide (CV 205±502) and cabergoline
(CAB) treatments in 39 patients with prolactinoma.
STUDY DESIGN All 39 patients were treated ®rst with
quinagolide for 12 months and then with cabergoline
for 12 months. A wash-out period was performed in all
patients after 12 months of both treatments in order to
evaluate recurrence of hyperprolactinaemia.
PATIENTS Twenty-three patients with microprolacti-
noma (basal serum PRL levels 1620±18750 mU/l) and
16 patients with macroprolactinoma (basal serum PRL
levels 4110±111000 mU/l), previously shown to be
intolerant of bromocriptine. All patients had gonadal
failure and 11 patients with macroprolactinoma had
visual ®eld defects. Five patients with macro- and one
with microprolactinoma had previously undergone
surgery.
STUDY PROTOCOL The starting doses of quinagolide
and CAB were 0´075 mg/day and 0´5 mg/week, respec-
tively, subsequently increased up to 0´6 mg once daily
and 1´5 mg twice weekly, respectively. Serum PRL
levels were measured monthly for the ®rst 3 months
and then quarterly for 12 months. PRL levels were
assayed weekly for the ®rst month and then monthly
during the wash-out period. Tumour shrinkage was
evaluated by serial magnetic resonance imaging (MRI)
studies of the hypothalamus±pituitary region at study
entry and after 6 and 12 months of both treatments in
micro- and macroprolactinomas.
RESULTS After 12 months of quinagolide treatment,
serum PRL levels normalized in all 23 patients with
microprolactinoma (100%) and in 14 out of 16 with
macroprolactinoma (87´5%). A tumour volume reduc-
tion of greater than 80% was documented by MRI
studies in ®ve of 23 (21´7%) patients with micro-
prolactinoma and in four of 16 (25%) with macro-
prolactinoma. All patients had recurrence of
hyperprolactinaemia after 15±60 days withdrawal of
quinagolide treatment. However, before starting CAB
treatment basal PRL levels were signi®cantly lower
than before quinagolide treatment both in micropro-
lactinomas (4667´4 6 714´7 vs. 2636´1 6 262´3 mU/l,
P 0´006) and in macroprolactinomas (24853´1 6
7566´7 vs. 3576´6 6 413´0 mU/l, P 0´013). After
12 months of CAB treatment, serum PRL levels
normalized in 22 out of 23 patients with micropro-
lactinoma (95´6%) and in 14 out of 16 with macro-
prolactinoma (87´5%). No difference in PRL nadir
was found after quinagolide and CAB treatments
both in micro 174´6 6 30´6 vs. 169´8 6 37´9 mU/l,
P 0´5) and in macroprolactinomas (277´5 6 68´4 vs.
341´8 6 95´2 mU/l, P 0´6). A tumour volume reduction
of greater than 80% was documented by MRI studies
in seven other patients with microprolactinoma
(30´4%) and in ®ve other patients with macroprolacti-
noma (31´2%). After CAB treatment, further tumour
shrinkage ranging 4±40% and 2±70% was observed in
12 micro- and seven macroprolactinomas, respec-
tively. The percentage of tumour shrinkage after
CAB was signi®cantly higher than that observed
after quinagolide in microprolactinomas (48´6 6 9´5
vs. 26´7 6 4´5%, P 0´046) but not in macroprolactino-
mas (47´0 6 10´6 vs. 26´8 6 8´4%, P0´2). The with-
drawal from CAB treatment, induced an increase in
serum PRL levels in all macroprolactinomas between
15 and 30 days, in 15 out of 23 microprolactinoma after
30 days, and in four patients after 2±4 months. In the
remaining four patients serum PRL levels remained
normal after 12 months of CAB withdrawal.
Both compounds were tolerated satisfactorily by all
patients. In the ®rst week of quinagolide treatment, 12
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patients reported nausea and postural hypotension,
which spontaneously disappeared during the second-
third week of treatment. None of the 39 patients
reported side-effects during CAB treatment.
CONCLUSIONS Both quinagolide and CAB treat-
ments, induced the normalization of serum PRL
levels in the great majority of patients with prolacti-
noma. Tumour shrinkage was recorded in 22±25% of
patients after quinagolide and in 30±31% after CAB
treatment. However, CAB induced notable tumour
shrinkage even in patients who had partial tumour
reduction after quinagolide. CAB treatment was toler-
ated better than quinagolide treatment in 12 out of 39
patients (30´7%). On this basis, both compounds can
be used as ®rst line treatment in prolactinomas, while
CAB is preferable in patients poorly tolerant to other
dopamine agonists. Finally, the long-lasting hypopro-
lactinemic effect of CAB allowed an intermittent treat-
ment schedule in eight out of 23 patients with
microprolactinomas with a better cost:effectiveness
ratio.
Pharmacotherapy with compounds with dopamine-agonist
activity is the current ®rst line treatment for both micro-
prolactinomas and macroprolactinomas (Vance et al., 1984;
Molitch et al., 1997; Colao & Lombardi 1998). The objectives
of therapy in these tumours are the control of PRL hypersecre-
tion with return to the eugonadal state, tumour shrinkage and
reversal of visual ®eld defects, restoration of pituitary function,
particularly in patients with macroprolactinoma, and ®nally, the
prevention of disease recurrence (Colao et al., 1998). In over
two decades, extensive experience has been accumulated by
using bromocriptine treatment that suppresses PRL secretion,
restores gonadal function and shrinks prolactinomas in
approximately 90% of cases (Vance et al., 1984). Other
compounds provided with similar bene®cial effects were
mesulergine, pergolide, and lisuride, but the experience with
these compounds in the treatment of hyperprolactinemic
syndromes is still limited (Grossman et al., 1985; Lamberts &
Quick, 1991). However, side-effects occur frequently at the
beginning of therapy with these drugs. The most important
problems are gastrointestinal disturbance (nausea with or
without vomiting), postural hypotension, dizziness and head-
ache. Side-effects are generally mild and transient but some-
times they necessitate reduction in drug dosage, thus preventing
the attainment of normoprolactinaemia (Grossman et al., 1985;
Liuzzi et al., 1985; Lamberts et al., 1991).
In a signi®cant proportion of patients side-effects are so
severe as to induce withdrawal from therapy. Side-effects are
considered to be due to the elevated drug levels reached in the
peripheral circulation after absorption, since most of these
compounds have a short half-life so that they have to be
administered two or three times daily. Moreover, in some
patients normoprolactinaemia is not achieved even after
increasing the dose of the drugs (20 mg/day for bromocriptine).
These patients are considered partially resistant to dopamine
agonists, but usually a poor therapeutic response is due to
dif®culty achieving a effective dose because of side-effects,
rather than to abnormalities at the D2 receptor level (Pellegrini
et al., 1989; Bevan et al., 1992; Colao et al., 1997a).
In recent years, new compounds have been developed with
the aim at providing drugs that are selective and long-lasting, so
as to allow disease control with better compliance (Brue et al.,
1992; Vilar & Burke, 1994; Biller et al., 1996; Colao et al.,
1997b). In particular, two compounds characterized by a
selectivity for the D2 receptor have received great attention for
their increased ef®cacy and tolerability: quinagolide (CV 205±
502) and cabergoline (CAB). In most patients with prolacti-
noma both quinagolide, a nonergot, and CAB, an ergot
derivative, have been demonstrated to normalize serum PRL
levels, restore gonadal function and reduce tumour mass
(Webster et al., 1994; Colao et al., 1998). In the majority of
studies the ef®cacy of quinagolide or CAB treatments was
compared to that of bromocriptine (BRC) while a comparison
of the effects of these two compounds has been investigated
only in one report (Giusti et al., 1994) demonstrating that the
clinical effects of the two drugs are very similar. No study has,
however, investigated the effect of quinagolide and CAB
treatment withdrawal on serum PRL levels.
The aim of this study was to compare the effectiveness and
tolerability of a 12-month treatment with quinagolide and CAB
in 39 patients with prolactinoma. The effect of quinagolide and
CAB withdrawal was also investigated.
Patients and methods
Patients
Twenty-three patients with microprolactinoma (21 women and
two men; aged 23±54 years) and 16 with macroprolactinoma
(10 women and six men; aged 19±76 years) gave their written
informed consent to participate in this double treatment single
group cross-over study. Five patients with macroprolactinoma
and one with microprolactinoma had undergone previous
neurosurgery, but hyperprolactinaemia and/or residual tumour
mass persisted. At study entry, serum PRL levels ranged from
1620 to 18750 mU/l in microprolactinomas and 4100±
111000 mU/l in macroprolactinomas. All men had loss of
libido and impotence, whereas all women had menstrual
disturbance; 19 women had spontaneous or expressible
galactorrhoea. Bitemporal hemianopia was shown by visual
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perimetry in 11 patients with macroprolactinoma, in ®ve of
these visual disturbances persisted after surgery. All patients
were considered to be intolerant of BRC treatment on the basis
of the appearance of moderate-to-severe side-effects (nausea,
vomiting, headache, postural hypotension or dizziness) after the
®rst administration of 2´5 mg of the drug. The side-effects were
considered by the patients to be so severe as to necessitate
treatment discontinuation.
Study protocol
Both quinagolide and CAB treatments were given for
12 months. Quinagolide was given orally at the starting dose
of 0´075 mg once daily and CAB was given orally at the starting
dose of 0´5 mg once weekly; in order to obtain normoprolacti-
naemia, the dose of the drugs was increased up to 0´6 mg daily
and 1´5 mg twice weekly, respectively. Basal PRL levels were
measured as average value of a 6 h pro®le with hourly sampling
(0800±1400 h). After 1, 2, 3, 6, 9 and 12 months of quinagolide
and CAB treatments, fasting serum PRL levels were assayed in
the morning as an average of three samples. The recurrence of
hyperprolactinaemia was investigated in all patients after
withdrawal from quinagolide and CAB treatment: serum PRL
levels were assayed weekly for the ®rst month and then
monthly. In the present series hyperprolactinaemia reccurred
after 15±60 days of quinagolide withdrawal and after 15 days to
4 months of CAB withdrawal. In four out of 39 patients,
recurrence of hyperprolactinaemia after CAB withdrawal could
not be investigated since they still had normal PRL levels (see
Results section below). Gonadal status was investigated before
and quarterly during follow-up. Routine clinical and hormonal
evaluations showed no thyroid or adrenal abnormalities in any
of the 39 patients.
Magnetic resonance imaging studies
MRI studies were carried out using a superconductive magnetic
resonance (0´5±1´0 Tesla) and super®cial coil in axial, coronal
and sagittal sections. The acquisitions were spin echo with 1000
msec repetition time and 40±120 msec echo time. Tumour
shrinkage was de®ned as a reduction to the pretreatment tumour
volume of greater than 80%, calculated using the formula:
volume  height ´ length ´ width ´ p/6.
MRI studies were performed at study entry, after 6 and
12 months of treatment with quinagolide and after 6 and
12 months of CAB treatment both in micro- and macropro-
lactinomas.
Visual perimetry
At baseline the evaluation of visual ®eld defects, by
Goldmann±Friedmann perimetry, and visual acuity was per-
formed in all patients with macroprolactinoma. The ophthalmo-
logical examination was repeated every 3±6 months during the
follow-up in patients with visual disturbance.
Assay
Serum PRL levels were assessed by IRMA using commercial
kits (Radim, Pomezia, Italy). The intra- and interassay
coef®cients of variation were 5% and 7%, respectively. The
normal ranges were below 750 mU/l in women and below
450 mU/l in men.
Statistical analysis
The statistical analysis of the percent PRL suppression after
quinagolide and cabergoline treatment was performed using the
Student's t-test for paired data and are expressed as Mean
6 SEM. The 95% CI for all statistical analyses are also
reported.
Results
Effect of quinagolide and CAB treatment on serum PRL
levels
After 3 months of quinagolide, serum PRL levels normalized in
19 out of 23 patients with microprolactinoma (82´6%) and in six
out of 16 with macroprolactinoma (37´5%). In the remaining
patients the dose was increased up to 0´3±0´45 mg/daily. After
6 months of treatment, serum PRL levels normalized in all
patients with microprolactinoma and in 13 out of 16 with
macroprolactinoma (81´2%). In these 3 patients with residual
hyperprolactinaemia (nos. 33, 38 and 39, Table 1), the dose of
quinagolide was increased up to 0´6 mg/day; serum PRL levels
normalized in one of these patients (no. 33) after 12 months of
treatment. Gonadal and sexual function recovered in all
patients, but ®ve women and one man with macroprolactinoma
had persistent gonadal dysfunction (libido and potency failure
in the man, oligomenorrhoea in women). Galactorrhoea
resolved in all patients. After quinagolide treatment with-
drawal, serum PRL levels increased in all patients (see below),
without reaching basal values. In fact, before starting CAB
treatment basal PRL levels were signi®cantly lower than
before quinagolide treatment both in micro- (2636´1 6 262´3
vs. 4667´4 6 714´7 mU/l P 0´006, 95% CI 658´7±3403´9)
and macroprolactinomas (3576´6 6 413´0 vs. 24853´1 6
7566´7 mU/l, P 0´013, 95% CI 5082´4±37470´8). After
3 months of CAB treatment, serum PRL levels normalized in
18 out of 23 patients with microprolactinoma (78´2%), and in
eight out of 16 with macroprolactinoma (50%). The dose of
Medical treatment of prolactinomas 55
q 2000 Blackwell Science Ltd, Clinical Endocrinology, 53, 53±60
CAB was then increased up to 1 mg twice a week; after
6 months serum PRL levels normalized in another eight patients
(four micro- and four macroprolactinomas). After 6 months of
CAB treatment gonadal and sexual function recovered in all
patients with microprolactinoma and also in four out of six
patients with macroprolactinoma, who had persistence in
gonadal disturbances after 12 months of quinagolide treatment.
After 12 months, in the remaining ®ve patients (one micro- and
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Table 1 Effects of a 12-month treatment with quinagolide and cabergoline on serum PRL levels and tumour shrinkage in the 39 patients with
prolactinoma included in the study
Treatment with Quinagolide Treatment with Cabergoline
Serum PRL levels Serum PRL levels
(mU/l) (mU/l)
Patient Maximal dose Tumour shrinkage Maximal dose Tumour shrinkage
(sex,age) basal nadir (mg/day) (%) basal nadir (mg/week) (%)
Microprolactinomas
1 f,24 2802 270 0´075 26 1269 48 1 31
2 f,23 2010 27 0´075 93´4 1470 720 3 4
3 f,25 4140 60 0´075 100 1680 45 1 ne
4 f,24 1818 120 0´075 44 4290 48 2 100
5 f,28 4350 354 0´45 10 2145 159 1 30
6 f,29 3690 63 0´075 35 2295 171 1 40
7 f,25 6000 45 0´075 31 6330 3 1 100
8 f,34 4890 30 0´075 100 3000 63 1 ne
9 f,33 4770 420 0´3 9 4500 165 1 15
10 m,33 6900 180 0´075 18 4980 330 1 25
11 f,37 3450 300 0´075 10 2190 600 2 6
12 f,36 3000 21 0´075 100 3090 102 1 ne
13 m,40 18750 108 0´075 100 3750 90 1 ne
14 f,48 3840 207 0´075 15 915 3 1 100
15 f,40 4860 222 0´075 11 4320 195 1 30
16 f,54 7800 30 0´075 37 2880 39 1 100
17 f,41 4110 75 0´075 30 3600 120 1´5 100
18 f,38 2740 90 0´075 40 2460 90 1 14
19 f,32 3480 270 0´075 18 2910 342 2 9
20 f,43 4650 516 0´3 0 1512 246 1 12
21 f,38 1620 114 0´075 25 84 222 1 8
22 f,30 2730 75 0´075 37 1560 51 1 100
23 f,40 4950 420 0´3 18 2100 54 1 100
Macroprolactinomas
24 f,23 7920 30 0´075 31 5190 45 1 37
25 f,26 10200 342 0´3 0 1740 1140 3 3
26 f,30 7800 42 0´45 100 5700 210 1 ne
27 m,19 4950 9 0´075 100 1290 426 1 ne
28 m,21 5550 330 0´3 0 3900 1260 3 2
29 m,22 111000 66 0´45 83 3510 450 1 0
30 f,23 7650 54 0´075 48 2190 33 3 100
31 f,27 15000 36 0´075 87´7 5400 964 1 0
32 f,26 19500 252 0´45 20 1725 99 1´5 43
33 f,33 37380 600 0´6 6 7110 21 2 100
34 m,29 13890 315 0´3 7 2730 291 1 20
35 f,40 16500 540 0´3 9 3360 30 3 83
36 f,54 69000 189 0´075 19´7 2400 390 1 24
37 m,76 60600 45 0´075 63´8 2700 30 1 70
38 f,24 6600 780 0´6 0 4590 390 1 90
39 f,31 4110 810 0´6 0 3690 90 1´5 86
ne, not evaluable due to tumour disappearance with quinagolide treatment.
four macroprolactinomas) the dose of CAB was increased up to
3 mg/week: serum PRL normalization was achieved in three
patients (nos. 2, 30 and 35, Table 1). In the remaining two
patients with macroprolactinoma (nos. 25 and 28, Table 1)
serum PRL levels remained mildly elevated (1140±1260 mU/l).
After quinagolide and CAB treatments, no difference was
found in PRL nadir in both micro- (174´6 6 30´6 vs.
169´8 6 37´9 mU/l, P 0´5, 95%CI±89´2±98´8) and in macro-
prolactinomas (277´5 6 68´4 vs. 341´8 6 95´2 mU/l, P 0´6,
95%CI±317´8±189´2) as well as in the percent PRL suppres-
sion both in micro- (95´5 6 0´7 vs. 92´4 6 2´3%, P 0´207,
95%CI±1´78±7´76, respectively) and in macroprolactinomas
(96´8 6 1´3 vs. 88´1 6 4´4%, P 0´078, 95%CI±1´09±18´57,
respectively).
Effect of quinagolide and CAB treatment withdrawal on
serum PRL levels
The withdrawal of quinagolide treatment induced an increase in
serum PRL levels in all 39 patients after 15±60 days. The
withdrawal of CAB treatment, induced an increase in serum
PRL levels in all patients with macroprolactinomas after 15±
30 days, and in 15 of 23 patients with microprolactinomas after
1 month. In four patients (nos. 1, 6, 8 and 21, Table 1)
recurrence of hyperprolactinaemia was observed after 2±
4 months. In the remaining four patients (nos. 7, 12, 13 and
23, Table 1) serum PRL levels remained normal after
12 months.
Effects on tumour size
After 6 months of treatment with quinagolide at a dose of
0´075±0´45 mg/day, tumour volume reduction to greater than
80% of the original size was documented by MRI studies in ®ve
out of 23 patients with microprolactinoma (21´7%) (nos. 2, 3, 8,
12 and 13, Table 1) and in four out of 16 with macroprolactinoma
(25%) (nos. 26, 27, 29 and 31). An example is shown in Fig. 1
(no. 29). On MRI, the tumour mass disappeared completely in
four of the ®ve patients with microprolactinoma (nos. 3, 8, 12
and 13) and in two of the four with macroprolactinoma (nos. 26
and 27) after 12 months of treatment. Signi®cant improvement
in visual ®eld defects was obtained in one out of six
nonoperated patients with macroprolactinoma (no. 27). After
6 months of treatment with CAB at a dose of 0´5±2 mg/week,
tumour volume reduction to less than 80% of the original size
was documented by MRI in seven other patients with
microprolactinoma (30´4%) (nos. 4, 7, 14, 16, 17, 22 and 23,
Table 1) and in ®ve other patients with macroprolactinoma
(31´2%) (nos. 30, 33, 35, 38 and 39, Table 1). An example is
shown in Fig. 2 (patient no. 35). After 12 months of CAB
treatment, the tumour mass disappeared completely on MRI in
six of the seven patients with microprolactinoma (nos. 14, 16,
17, 22 and 23 Table 1) and in two of the ®ve with
macroprolactinoma (nos. 30,33, Table 1). Improvement in
visual ®eld defects was obtained in other two out of six
nonoperated patients (nos. 30 and 33) with macroprolactinoma.
No change in visual ®eld defects was observed with either
quinagolide or CAB in the ®ve patients with macroprolacti-
noma who had previously undergone surgery (nos. 25, 28, 32,
36 and 37 Table 1). After CAB treatment, further tumour
shrinkage of 4±40% and 2±70% was observed in 12 micro-
prolactinomas and seven macroprolactinomas, respectively.
Medical treatment of prolactinomas 57
q 2000 Blackwell Science Ltd, Clinical Endocrinology, 53, 53±60
Fig. 1 Magnetic resonance imaging with coronal sections of one
example of macroprolactinoma (no. 29, Table 1) (A) before and (B)
after six months treatment with quinagolide at a dose of 0´075±
0´45 mg/day.
The percent tumour shrinkage after CAB was signi®cantly
higher than that observed after quinagolide in microprolacti-
nomas (48´6 6 9´5 vs. 26´7 6 4´5%, P 0´046, 95%CI±43´4±
0´5) but not in macroprolactinomas (47´0 6 10´6 vs.
26´8 6 8´4%, P 0´2, 95%CI±53´1±12´7).
Drug safety and tolerability
At the initiation of quinagolide treatment, seven of 23 patients
with microprolactinoma (30´4%) and ®ve of 16 with macro-
prolactinoma (31´2%) reported mild side-effects, such as
nausea and postural hypotension. These symptoms disappeared
spontaneously during the second to third weeks of treatment in
all 12 patients. The treatment with CAB was optimally tolerated
by all patients, no side-effects were reported by any patient
including the 12 patients who had tolerance-related problems at
the beginning of quinagolide treatment. All patients showed an
excellent compliance to both treatments.
Discussion
The results of the present study show that the two selective D2
agonists, quinagolide and CAB, currently available in most
European countries are similarly effective, in terms of normal-
ization of serum PRL levels in the treatment of prolactinomas.
In contrast, treatment with CAB induced further tumour
shrinkage in 52´1% of micro- and 43´7% of macroprolactinomas,
inducing a higher percent tumour reduction in microprolactino-
mas. As far as tolerability is concerned, both compounds were
tolerated well by patients who had reported intolerance of BRC,
while CAB was tolerated better than quinagolide by 30´7% of the
patients. In addition, our study reported the persistence of
normoprolactinaemia in four out of 23 patients with micro-
prolactinoma (17´3%) after 12 months of CAB withdrawal.
Both CAB (Ferrari et al., 1986; Ciccarelli et al., 1989;
Webster et al., 1992) and quinagolide (Khalfallah et al., 1990;
Van Der Lely et al., 1991) have been used as long-lasting
hypoprolactinemic drugs in recent years and they have been
shown as useful alternative to BRC in the treatment of
hyperprolactinemic syndromes. The treatment with these
dopamine-agonist compounds has been demonstrated to
normalize serum PRL levels, reduce tumour mass and restore
gonadal function also in patients resistant or intolerant to BRC
(Van Der Lely et al., 1991; Brue et al., 1992; Vilar et al., 1994;
Colao et al., 1995; Colao et al., 1997a; present study).
However, the ef®cacy of CAB and quinagolide was generally
evaluated in different cohorts of patients and data obtained in
the same group of patients treated with both drugs are scant. In
the only study reported so far, Giusti et al. (1994) demonstrated
that CAB and quinagolide have similar ef®cacy in lowering
PRL levels and resolving the clinical symptoms. However, the
prevalence of adverse reactions was signi®cantly higher during
quinagolide than during CAB treatments (Giusti et al., 1994).
The effect of a previous administration of a dopamine agonist
modi®es the response to the subsequent drug with similar
pharmacological properties either for PRL level decrease and
tumour shrinkage. In fact, in the present cohort of patients
serum PRL levels before starting CAB treatment were
signi®cantly lower than at study entry while the effect on
tumour shrinkage could not be evaluated in six patients
achieving total disappearance of their tumours after
12 months of quinagolide treatment. On the other hand, by
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Fig. 2 Magnetic resonance imaging with coronal sections of another
example of macroprolactinoma (no. 35, Table 1) (A) before and (B)
after six months treatment with cabergoline at a dose of 0´5±3 mg/
week.
calculating the percent tumour reduction obtained with both
drugs, it was demonstrated that after CAB treatment further
tumour shrinkage was observed in 12 micro- (52´2%) and seven
macroprolactinomas (43´7%). This con®rms previous data
reporting a notable tumour shrinking effect of CAB treatment
in prolactinomas even when administered at low doses (Biller et
al., 1996; Colao et al., 1997b; CannavoÁ et al., 1999; Verhelst et
al., 1999). However, hyperprolactinaemia frequently recurs
after drug withdrawal, suggesting that at least some lactotrophs
have escaped (Lloyd et al., 1975; Landolt et al., 1985).
Therefore, although the results of studies aiming at
comparing the effect of two dopamine agonists given
sequentially should be considered carefully due to the study
design itself, the data presented in the current study can be
considered informative since they were collected in the same
cohort of prolactinoma-bearing patients. The treatment with
quinagolide and CAB was completely successful in the 23
patients with microprolactinoma since all achieved normopro-
lactinaemia, with restoration of gonadal function, and 21 of
them (91´3%) also obtained a signi®cant reduction in tumour
volume. It should be pointed out that in four out of 23 patients
with microprolactinoma, persistence of normoprolactinaemia
and normal gonadal function were still present after 12 months
CAB withdrawal. Whether this effect is due to the long-lasting
hypoprolactinemic effect of CAB or to real cure of the disease,
can not be differentiated. Neither compound was able to
normalize serum PRL levels in two of 16 patients with
macroprolactinoma (12´5%), even when administered at rather
high doses (0´6 mg/day and 3 mg/week, respectively). How-
ever, it should be considered that in 25 out of 39 patients,
normalization of serum PRL was obtained with very low doses
of CAB (0´5 mg twice a week) and quinagolide (0´075 mg twice
a day). Clearly, the schedule of drug administration for CAB
(twice a week) improved compliance during long-term
treatment. Patient compliance is a key factor in the evaluation
of therapy success in hyperprolactinemic patients since
treatment must be maintained for a very long period of time,
or even for life (Faglia, 1991). In a previous study (Colao et al.,
1997a) we demonstrated that CAB treatment was successful in
27 patients shown to be resistant to high dose BRC (20 mg/day)
and quinagolide (0´6 mg/day) treatment. CAB treatment at the
dose of 0´5±3 mg/week was able to normalize PRL levels in the
majority of these patients (78´9% in macroprolactinoma and
100% in microprolactinoma), probably due to the improved
tolerability which consented a progressive increase in CAB
dosage (Colao et al., 1997a). The results of the current study,
which was carried out in another cohort of patients, demon-
strated that treatment with CAB is undoubtedly better tolerated
than that with quinagolide.
In conclusion, our comparison of the effects of long-term
quinagolide and cabergoline treatments in patients with
prolactinomas, demonstrated that the effects of both these
dopamine-agonist compounds on clinical features (gonadal
failure, galactorrhoea, visual ®eld defects) and PRL normal-
ization were similar. However, cabergoline induced notable
tumour shrinkage even in patients who had partial tumour
reduction after quinagolide. Cabergoline was better tolerated in
approximately one-third of the patients. Therefore, it could be
used as a ®rst-line pharmacological treatment in prolactinomas,
particularly in macroprolactinomas, due to its potent effect in
reducing tumour mass at low weekly doses. Finally, the long-
lasting hypoprolactinemic effect of cabergoline may induce
cure of the disease in some patients with microprolactinoma
and may permit an intermittent schedule of treatment in others
(34´7% in the present series), with a better cost:effectiveness
ratio.
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